ArticleInvestigative ophthalmology & visual science2026
A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Purpose: To establish an in vitro model of smoking-associated oxidative injury to the corneal endothelium and evaluate an injury-mitigating factor. Methods: Primary human and porcine corneal endothelial cells (CEnCs) were exposed to hydroquinone (HQ; 0-150 µM, 48 hours). Outcomes included viability (ATP-based assay), reactive oxygen species (ROS), and apoptosis (TUNEL). Bulk RNA sequencing (RNA-seq) profiled HQ (Nrf2 and Hippo-Yap pathways) and HQ ± fibroblast growth factor 10 (FGF10) responses under moderate stress (cadherin/Wnt programs). FGF10 dose-response (1-100 ng/mL) identified 30 ng/mL for subsequent HQ ± FGF10 studies. Western blotting provided protein validation. Results: HQ caused dose-dependent loss of viability with increased ROS and apoptosis (EC50: 191.2 µM human; 151.2 µM porcine). RNA-seq showed induction of Nrf2 antioxidant/detoxification genes with attenuation of Hippo-Yap signaling. At 150 µM HQ, total Yap decreased and the pYap/Yap ratio increased, consistent with Yap inactivation. FGF10 improved viability across doses (1-100 ng/mL; plateau 30-100 ng/mL) and required cotreatment during HQ exposure. Using 30 ng/mL, FGF10 improved viability across HQ doses, reduced ROS at 100 to 150 µM, and decreased apoptosis at 50 to 100 µM. At 50 µM HQ, FGF10 increased cadherin/Wnt-related transcripts, while N-cadherin protein decreased and β-catenin remained stable, consistent with junctional remodeling rather than full endothelial-mesenchymal transition. Key injury and rescue phenotypes were consistent across species. Conclusions: Our study supports HQ as a translatable in vitro model of smoking-related oxidative stress in CEnCs. FGF10 shows injury-mitigating and pro-regenerative effects, supporting further preclinical evaluation to preserve endothelial integrity and potentially lessen reliance on transplantation in corneal endothelial dystrophies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.